Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...
MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...
Moore Kuehn Encourages FTSV, MINI, POPE, WAAS, and TLRA Investors to Contact Law Firm PR Newswire NEW YORK, March 4, 2020 NEW YORK, March 4, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Forty Seven, Inc. PR Newswire NEW YORK, March 3, 2020 NEW YORK, March 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
(FTSV) Alert: Johnson Fistel Investigates Proposed Sale of Forty Seven, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, March 2, 2020 SAN DIEGO, March 2, 2020 /PRNewswire/...
– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell...
MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the...
MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the...
-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 -- -- Updated Data from Ongoing Phase...
MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
